For most of the twentieth century, therapeutic hCG was manufactured by collecting urine from pregnant women, then subjecting it to a multi-step purification process designed to isolate the hormone from everything else present in the sample. This method, discussed in the context of hCG history in our article on hCG from discovery to therapy, remains in use in parts of the world today.
Urinary extraction requires large volumes of source material and extensive purification to reach pharmaceutical-grade purity, which historically made supply and consistency a meaningful manufacturing challenge.
Recombinant hCG is produced using genetic engineering rather than biological extraction. The gene responsible for producing hCG is inserted into laboratory cell lines, most commonly mammalian cell cultures, which are then grown under controlled conditions and prompted to manufacture the hormone directly.
Because this process happens entirely in a controlled laboratory environment rather than depending on collected human urine, recombinant production generally offers more consistent batch-to-batch purity and does not depend on a variable supply chain of donated urine.
Recombinant technology of this kind is not unique to hCG. The same general genetic engineering approach underlies the manufacture of many modern biologic pharmaceuticals, which is part of why regulatory agencies already have well-established review pathways for evaluating recombinant hormone products before they can be approved for clinical use.
Both manufacturing methods are capable of producing pharmaceutical-grade hCG when carried out under proper quality controls, and both remain in legitimate clinical use internationally. The key practical differences tend to be around production scalability, batch consistency, and manufacturing cost rather than any difference in how the final hormone behaves in the body, since the resulting molecule is structurally very similar either way.
Regulatory agencies require rigorous purity, potency, and safety testing for pharmaceutical hCG regardless of which manufacturing method was used, which is part of why hCG remains classified as a controlled prescription pharmaceutical rather than something that can be manufactured or sold informally.
Products claiming to be hCG that originate outside licensed pharmaceutical manufacturing and regulatory oversight, whatever their claimed source, carry meaningful risk around purity, actual hormone content, and contamination. This is a separate but related concern to the legal risks discussed in our article on off-label bodybuilding use of hCG.
Legitimate pharmaceutical hCG, whichever manufacturing method was used, only reaches patients through licensed pharmacies and clinics operating under national pharmaceutical regulation, including in the UAE.
REVIVE LAB UAE supplies non-prescription research peptides manufactured for laboratory and research use, an entirely separate category from pharmaceutical hCG production. REVIVE LAB UAE does not manufacture, sell, stock, or supply hCG in any form.